Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.40 |
| ▸ | NNMT | P40261 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.37 |
| ▸ | HCAR3 | P49019 | 4/20 | 0.37 |
| ▸ | GAA | P10253 | 5/20 | 0.36 |
| ▸ | MAPT | P10636 | 3/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.34 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acetone SCHEMBL12813654 | 0.99 | KDM4E (0.39) | KDM4ENNMTRAB9AHCAR3GAA | |
| SCHEMBL1256560 | 0.96 | KDM4E (0.39) | KDM4ENNMTRAB9AHCAR3GAA | |
| SCHEMBL28462853 | 0.93 | KDM4E (0.37) | KDM4ENNMTRAB9AHCAR3GAA | |
| Acetone SCHEMBL1019109 | 0.79 | MAPK1 (0.40) | KDM4ENNMTRAB9AHCAR3GAA | |
| Acetone SCHEMBL17732269 | 0.78 | MAPK1 (0.39) | KDM4ENNMTRAB9AHCAR3GAA | |
| SCHEMBL16767391 | 0.75 | KDM4E (0.37) | KDM4ENNMTHCAR3GAAMAPT | |
| SCHEMBL1445644 | 0.74 | MAPK1 (0.40) | KDM4ENNMTRAB9AHCAR3GAA | |
| SCHEMBL30914672 | 0.74 | MAPK1 (0.40) | KDM4ENNMTRAB9AHCAR3GAA | |
| Acetone SCHEMBL7024428 | 0.74 | HCAR3 (0.66) | HCAR3 | |
| SCHEMBL2487358 | 0.74 | NNMT (0.54) | NNMTHCAR3HDAC1HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 224 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010033598-A2 | SYSTEM AND METHOD FOR UTILIZING MICROBUBBLES AND LIPOSOMES AS VIRAL SEQUESTERING AGENTS | VERUS BIOTECHNOLOGY CORPORATION (US) | 2010-03-25 | — | — | WO | claimed |
| US-20100069814-A1 | SYSTEM AND METHOD FOR UTILIZING MICROBUBBLES AND LIPOSOMES AS VIRAL SEQUESTERING AGENTS | VERUS BIOTECHNOLOGY CORPORATION | 2010-03-18 | — | — | US | claimed |
| US-20090311698-A1 | DIAGNOSTIC ASSAY | WAYNE STATE UNIVERSITY | 2009-12-17 | — | — | US | claimed |
| US-20240226312-A1 | TREATMENT OF CANCER IN PATIENTS WITH SOLUBLE FR-ALPHA | IMMUNOGEN, INC. (US) | 2024-07-11 | — | — | US | disclosed |
| US-20240197898-A1 | SUBSTITUTED BENZO[5,6][1,4]DIAZEPINO[1,2-a]INDOLES FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | IMMUNOGEN, INC. | 2024-06-20 | — | — | US | disclosed |
| US-20240190956-A1 | CONJUGATES COMPRISING CELL-BINDING AGENTS AND CYTOTOXIC AGENTS | IMMUNOGEN INC (US) | 2024-06-13 | — | — | US | disclosed |
| US-20240182560-A1 | BIPARATOPIC FR-ALPHA ANTIBODIES AND IMMUNOCONJUGATES | IMMUNOGEN, INC. | 2024-06-06 | — | — | US | disclosed |
| US-20240142445-A1 | OPTICAL ANALYTE DETECTION SYSTEMS AND METHODS OF USE | GENALYTE INC (US) | 2024-05-02 | — | — | US | disclosed |
| US-RE49918-E1 | Cytotoxic benzodiazepine derivatives | IMMUNOGEN, INC. (US) | 2024-04-16 | — | — | US | disclosed |
| US-20240050666-A1 | METHODS AND DEVICES FOR MEDICAMENT DELIVERY | PALO ALTO RESEARCH CENTER INCORPORATED (US) | 2024-02-15 | — | — | US | disclosed |
| WO-2024035787-A2 | CLAUDIN-6 ANTIBODIES AND CONJUGATES THEREOF AND USES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-02-15 | — | — | WO | disclosed |
| WO-2010118169-A2 | HUMAN PROTEIN SCAFFOLD WITH CONTROLLED SERUM PHARMACOKINETICS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2010-10-14 | — | — | WO | disclosed |
| WO-2010033598-A2 | SYSTEM AND METHOD FOR UTILIZING MICROBUBBLES AND LIPOSOMES AS VIRAL SEQUESTERING AGENTS | VERUS BIOTECHNOLOGY CORPORATION (US) | 2010-03-25 | — | — | WO | disclosed |
| US-20100069814-A1 | SYSTEM AND METHOD FOR UTILIZING MICROBUBBLES AND LIPOSOMES AS VIRAL SEQUESTERING AGENTS | VERUS BIOTECHNOLOGY CORPORATION | 2010-03-18 | — | — | US | disclosed |
| US-20100012880-A1 | MAGNETIC PARTICLES AND METHODS OF MAKING AND USING THE SAME | COLUMBUS NANOWORKS, INC. (US) | 2010-01-21 | — | — | US | disclosed |
| US-20090311698-A1 | DIAGNOSTIC ASSAY | WAYNE STATE UNIVERSITY | 2009-12-17 | — | — | US | disclosed |
| EP-2125007-A2 | CONJUGATES OF SYNTHETIC TLR AGONISTS AND USES THEREFOR | Regents of the University of California (US) | 2009-12-02 | — | — | EP | disclosed |
| EP-2062271-A2 | MAGNETIC PARTICLES AND METHODS OF MAKING AND USING THE SAME | Columbus Nanoworks, Inc. (US) | 2009-05-27 | — | — | EP | disclosed |
| WO-2008115319-A2 | CONJUGATES OF SYNTHETIC TLR AGONISTS AND USES THEREFOR | REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2008-09-25 | — | — | WO | disclosed |
| WO-2008030862-A2 | MAGNETIC PARTICLES AND METHODS OF MAKING AND USING THE SAME | COLUMBUS NANOWORKS, INC. (US) | 2008-03-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240197898-A1 | SUBSTITUTED BENZO[5,6][1,4]DIAZEPINO[1,2-a]INDOLES FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | MKI67, GABBR1, GABBR2 | KDM4E 908/4885NNMT 3756/4885RAB9A 3371/4885 |
| US-20240190956-A1 | CONJUGATES COMPRISING CELL-BINDING AGENTS AND CYTOTOXIC AGENTS | PCNA, EPCAM, MKI67 | KDM4E 1222/4885NNMT 1054/4885RAB9A 3111/4885 |
| US-20240226312-A1 | TREATMENT OF CANCER IN PATIENTS WITH SOLUBLE FR-ALPHA | FOLR1, FOLR2, FRS2 | KDM4E 3874/4885NNMT 3809/4885RAB9A 2549/4885 |
| US-20240182560-A1 | BIPARATOPIC FR-ALPHA ANTIBODIES AND IMMUNOCONJUGATES | FOLR2, FOLR1, TFRC | KDM4E 4716/4885NNMT 4593/4885RAB9A 2944/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.